As of 2026-03-23, the EV/EBITDA ratio of Y-mAbs Therapeutics, Inc (YMAB) is -15.86. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. YMAB's latest enterprise value is 328.95 mil USD. YMAB's TTM EBITDA according to its financial statements is -20.75 mil USD. Dividing these 2 quantities gives us the above YMAB EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 18.9x | 16.0x |
| Forward P/E multiples | 19.0x - 25.1x | 21.2x |
| Fair Price | (7.30) - (7.27) | (7.11) |
| Upside | -184.7% - -184.4% | -182.6% |
| Date | EV/EBITDA |